April 1, 2026 4:42pm

Philosophically, Occam's Razor is defined as to eliminate unnecessary variables in arguments, helping to clarify reasoning and focus on essential elements. This means that when faced with competing hypotheses, one should select the one that makes the fewest assumptions.

The market and C&GT sector may not be out of the woods yet; until there’s “some type of all-clear announcement,” trading still could “remain volatile” in the short term

Investors will get more clues on the path forward for the U.S.-Iran war at 9 p.m. ET, with President Trump addressing the nation

RMi collects, curates, interprets and disseminates cell and gene therapy sector (C&GT) fact-based news, trustable and verified intel of share pricing data bridging the gap to an investment decision

Never leave a retail investor uninformed!  It’s not always time to buy or sell; but it is time to KNOW why!

I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others will not say or write about – facts in evidence!  I’m NOT at all writing a doom-and-gloom predictions as I am more frequently right than consequentially wrong; I am mostly EARLY in my prognostications!

RMi Pre-opening: I’m thankful for upside yet anxious … https://www.regmedinvestors.com/articles/14368   

I chose to speak-up when many analysts, brokers and commentators have shut-up!

 

What happened and some of the whys with the numbers behind

… it’s NOT always about BUYs/SELLs … it’s about knowing when and what!

 

Wednesday: The Dow closed UP +223.86 points or +0.48%, the S&P closed UP +46.80 points or +0.72% while the Nasdaq closed UP +250.319 points or +1.16%

  • Theme of the session: hope to an end to the U.S.-Iran war

Wednesday’s (my) 40-company covered sector’s advance/decline line opened positive with 34 incliners, 3 decliners and 3 flats, ending with a positive close of 29 incliner, 8 decliners and 3 flats

  • Sentiment’s not out of the woods., let’s see how many consecutive sessions going forward i.e., follow-through

Henry’omics: We need to more than consider the economic/political environment to comprehend the cause and effect of the macro versus micro data affecting “our” universe of cell and gene therapy (C&GT) sector

  • U.S. business inventories unexpectedly fell in January amid a large ‌decline in stocks at wholesalers. Inventories ​dipped 0.1% after being unchanged in December. Economists had expected that inventories, a ‌key component of ⁠GDP and one of the most volatile, would edge up 0.1% in January. Wholesale inventories dropped 0.5% while stocks at manufacturers edged up 0.1%. Business inventories added to the 0.7% annualized GDP growth pace in the fourth quarter, ‌despite marking their 3rd ​straight Q’s decline. Business ‌sales increased 0.3% in January ​after rising ​0.7% in December.
  • ISM manufacturing tops estimates as prices index jumps. Factory activity in the U.S. expanded in March, boosted by a gain in production. The ISM manufacturing index, a measure of firms reporting expansion for the period, hit 52.7 for the month, 0.3 points above February and slightly better than the 52.4 consensus estimate. Within the survey, the production index increased 1.6 points to 55.1 and supplier deliveries rose 3.8 points to 58.9. Prices index soared to 78.3, an increase of 7.8 points. Employment was little changed at 48.7.

The CBOE Fear (VIX) index, Wednesday closed at 24.61, after Tuesday’s 25.39, Monday’s 30.61, Friday’s 30.87, Thursday’s 28.31 and last Wednesday’s 25.40

Metrics: Wednesday …

  • The RUT was up +16.00 points or +0.64%,
  • The XLV was up +1.12 points or +0.76%,
  • The NBI was up +34.92 points or +0.60%;
  • The XBI was up +0.82 points or +0.64%
  • The IWM was up +1.60 or +0.65%;
  • The IBB was up +1.28 points or +0.76%,
  • The VIX was down -0.64 points or -2.53% at to 24.61

 

Q2/26 – 1 positive close

  • Q1 -March – 9 positive and 13 negative closes
  • February – 1 holiday, 8 negative and 11 positive sessions
  • January – 2 holidays, 2 neutral, 9 negative and 9 positive closes

 

Wednesday Closing UP (10 of 29)

  • IQVIA Holdings (IQV +$1.86 after Tuesday’s +$4.38 after Monday’s +$2.31 after Friday’s -$5.52),
  • CRISPR Therapeutics (CRSP +$1,24 after Tuesday’s +$3.23 after Monday’s -$1.41 after Friday’s -$1.80),
  • Entrada Therapeutics (TRDA +$0.86),
  • Vertex (VRTX +$0.72 after Tuesday’s +$3.38 after Monday’s +$10.09 after Friday’s -$20.67),
  • BioNTech (BNTX +$0.54 after Tuesday’s +$3.63 after Monday’s -$0.43 after Friday’s -$1.78),
  • uniQure NV (QURE +$0.54),
  • Ultragenyx Pharmaceuticals (RARE +$0.47),
  • Intellia Therapeutics (NTLA +$0.45),
  • AxoGen (AXGN +$0.45),
  • Mesoblast (MESO +$0.42),

Flat (3)

  • Harvard Apparatus RT (OTCQB: HRGN)
  • Generation Bio (GBIO) – acquired
  • MiMedx (MDXG)

Wednesday’s Closing DOWN (8 of 8):

  • Alnylam Pharmaceuticals (ALNY -$2.16 after Tuesday’s +$14.80 after Monday’s -$1.27 after Friday’s -$10.80),
  • Moderna (MRNA -$0-.77 after Tuesday’s +$2.57 after Monday’s -$1.33 after Friday’s -$4.01),
  • Wave Life Sciences (WVE -$0.42),
  • Capricor Therapeutics (CAPR -$0.28 after Tuesday’s +$2.63 after Monday’s -$1.13),
  • Supernus Therapeutics (SUPN -$0.25 after Tuesday’s+$2.34),
  • Prime Medicine (PRME -$0.09),
  • Brainstorm Cell Therapeutics (BCLI -$0.0798),
  • DYNE Therapeutics (DYN -$0.03),

 

The Bottom Line: More of the … WHY and a lot of what ifs …

No April Fools’ Day … market stays up, up and still away!

For now ...

The S&P 500 has averaged a gain of nearly 0.3% on April 1 going back to the index’s inception, the Dow has averaged a gain of 0.2%, while the Nasdaq has averaged a gain of 0.4%.

Tonight’s speech from the White house will set the course of the market …

Key … ahead of national address, President Trump says Strait of Hormuz must be 'open, free and clear' before ceasefire talks …

  • The president's speech, his 1st major public address since the war began, comes roughly a week ahead of his originally stated 4-to-6-week timeline for war with Iran.
  • Throughout the 5 weeks of conflict so far, Iran's closure of the Strait of Hormuz and attacks on the wider Gulf region have thrown the market into disarray.
  • Prices on Brent and WTI have soared by more than 40% each, pushing US gasoline prices at the pump over $4 per gallon nationally months ahead of the midterm elections.
  • Prices on fertilizer, iron ore, European natural gas, and other commodities have also surged throughout the conflict.
  • The war is now expected to materially impact economic growth both in the US and globally. <Yahoo Finance>

 

April – 1st week

  • 4/1 – Wednesday closed positive with 29 incliners, 8 decliners and 3 flats

March – 5th week

  • 3/31 – Tuesday closed positive with 36 incliners, 2 decliners and 2 flats
  • 3/30 - Monday closed negative with 12 incliners, 26 decliners and 2 flats

March – 4th week:

  • 3/27 – Friday closed negative with 1 incliner, 36 decliners and 3 flats
  • 3/26 – Thursday closed negative with 15 incliner, 22 decliners and 3 flats
  • 3/25 – Wednesday closed positive with 30 incliners, 5 decliners and 5 flats
  • 3/24 – Tuesday closed negative with 11 incliner, 27 decliners and 2 flats
  • 3/23 - Monday closed positive with 26 incliners, 12 decliners and 2 flats

 

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there – closed end funds” (BUY, SELL, VC and multiple operating roles) with gray, loss of hair and a readership following with real numbers to prove it!

 

Why do I keep repeating, framed in a different para, so investors can make the connection

The top three (3) performing in the session:    Winners

  • Wednesday: IQIA Holdings (IQV), Vertex (VRTX) and CRISPR Therapeutics (CRSP)
  • Tuesday: Alnylam Pharmaceuticals (ALNY), Arrowhead Pharmaceuticals (ARWR) and IQIA Holdings (IQV)
  • Monday: Vertex (VRTX), IQIA Holdings (IQV) and Vericel (VCEL)
  • Friday: Wave Life Sciences (WVE)

The worst three (3) in the session: Losers

  • Wednesday: Moderna (MRNA), Alnylam Pharmaceuticals (ALNY) and Wave Life Sciences (WVE)
  • Tuesday: Sangamo Therapeutics (SGMO) and Voyager Therapeutics (VYGR)
  • Monday: Alnylam Pharmaceuticals (ALNY), Moderna (MRNA) and CRISPR Therapeutics (CRSP)
  • Friday: Vertex (VRTX), Alnylam Pharmaceuticals (ALNY) and IQVA Holdings (IQV)

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.